This protocol addresses Glycogen storage disease type IV (GSD IV) in patients who have hypertrophic cardiomyopathy (HCM) with no dilated cardiomyopathy. The cardiac phenotype present directly guides the treatment approach outlined here.
Hypertrophic cardiomyopathy is confirmed; dilated cardiomyopathy is absent. This distinction is clinically significant and determines which therapeutic strategy applies in the context of GSD IV.
Management in this setting may include a beta-1-selective adrenergic blocking agent.
The complete regimen — including agent selection rationale and the full clinical algorithm — is available in the structured protocol below.
DOI: 10.1016/j.ymgme.2023.107525
For individuals with HCM, use of β1-selective β-blockers, such as metoprolol, is reasonable.
View source ↗